Please assess the completion status of the following clinical trial:

Trial Title: Denosumab Adherence Preference Satisfaction Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory postmenopausal women based on medical history~* \> or = 55 years of age at the start of screening~* Screening bone mineral density (BMD) values (g/cm²), at the lumbar spine OR femoral neck OR total hip that occur within the specified ranges based on the particular scanner that is used. At least 2 lumbar vertebrae must be evaluable by Dual X-ray Absorptiometry (DXA), or at least one hip must be evaluable by DXA~* Provide written informed consent before any study specific procedure is performed.~Exclusion Criteria:~* Any disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures~* Hyper- or hypothyroidism; however, stable subjects, in the investigator's opinion, on thyroid hormone replacement therapy are allowed~* Current hyper- or hypoparathyroidism~* Current hypo- or hyper calcemia based on the central laboratory reference ranges for albumin-adjusted serum calcium~* Rheumatoid arthritis, Paget's disease, Cushing's disease, hyperprolactinemia, or cirrhosis of the liver~* Any metabolic bone disease, e.g. osteomalacia or osteogenesis imperfecta, which may interfere with the interpretation of the findings~* Any symptomatic vertebral fracture within 3 months prior to screening~* Previous participation in clinical trials with denosumab~* Vitamin D deficiency \[25(OH) vitamin D level \< 20 ng/mL (\<49.9 nmol/L)\]~* Contraindicated to alendronate therapy; contraindications for alendronate therapy include:~  1. Abnormalities of the esophagus, which delay esophageal emptying such as stricture or achalasia.~ 2. Inability to stand or sit upright for at least 30 minutes.~ 3. Hypersensitivity to alendronate (ALN) or other constituents of ALN tablets.~* Any known prior bisphosphonate use~* Currently enrolled in or has not yet completed at least 1 month since ending other investigational device or drug trail (s), or subject is receiving other investigational agent(s).

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Sequence B (Type: OTHER): When a subject meets all eligibility criteria and signs the informed consent, they will be randomized in a 1:1 allocation to one of the two treatment Sequences. Subjects randomized to treatment sequence B will receive 70 mg oral alendronate QW for 1-year (Treatment period 1) followed by denosumab 60 mg Q6M SC for 1 year (Treatment Period 2).
- Treatment Sequence A (Type: OTHER): When a subject meets all eligibility criteria and signs the informed consent, they will be randomized in a 1:1 allocation to one of the two treatment sequences. Subjects randomized to treatment sequence A will receive 60 mg denosumab Q6M SC for 1-year (Treatment period 1) followed by oral alendronate 70 mg QW for 1 year (Treatment period 2).

Based on this trial design, predict the completion outcome and termination type (if applicable).